Claritin patent hearing
This article was originally published in The Tan Sheet
Executive Summary
Federal Circuit Court of Appeals will hear oral arguments April 8 in Schering-Plough's appeal of lower court ruling that its desloratadine patents are invalid. New Jersey federal judge ruled in August that Schering cannot rely on patent claims covering desloratadine (Clarinex) to keep generic versions of Claritin off the OTC market before 2004 (1"The Tan Sheet" Aug. 12, 2002, p. 3)...
You may also be interested in...
Desloratadine Patent Claims No Bar To Generic Claritin, Judge Says
Schering-Plough will not be able to rely on patent claims covering desloratadine to keep generic versions of its Claritin antihistamine off the OTC market before 2004 if a federal judge's ruling is upheld on appeal
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.